Foldrx
Pharmacy in Cambridge, MA
Our goal is to discover, evolve, and commercialize innovative therapies to treat patients afflicted with diseases caused by the misfolding of specific proteins. We're dedicated to developing disease-modifying therapies. Most marketed drugs target the consequence rather than the cause of disease and therefore treat only disease symptoms. We're targeting the cause of disease. We're targeting the cause of disease with the aim of delivering drugs that will stabilize or reverse disease. Our lead drug for TTR Amyloidosis, tafamidis (Fx-1006A) is currently in Phase II/III clinical trials.